Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals

  title={Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals},
  author={Donald S Chen and R Marsh and Judith A. Aberg},
  journal={Expert Review of Anti-infective Therapy},
  pages={921 - 928}
Pneumocystis jiroveci pneumonia remains one of the major worldwide contributors to the morbidity and mortality of those with HIV infection. The mainstay of therapy for treatment is trimethoprim–sulfamethoxazole (TMP–SMX); however TMP–SMX may be associated with significant side effects and intolerability. In addition, TMP–SMX has a moderate pill burden with three- to four-times daily dosing schedule. Patients unable to tolerate TMP–SMX are confronted with either parenteral therapy or other oral… 
Combined Treatment of Heterocyclic Analogues and Benznidazole upon Trypanosoma cruzi In Vivo
Cure assessment through hemocultive and PCR approaches showed that Bz did not provide a parasitological cure, however, DB766 alone or associated with Bz cured ≥13% of surviving animals.
Efficacy, Safety, and Dose of Pafuramidine, a New Oral Drug for Treatment of First Stage Sleeping Sickness, in a Phase 2a Clinical Study and Phase 2b Randomized Clinical Studies
Pafuramidine for the treatment of first stage HAT was comparable in efficacy to pentamidine after 10 days of dosing, and results support continuation of the development program for pafur amidine into Phase 3.
Estudos in vitro e in vivo da atividade biológica de fluorquinolonas, tiossemicarbazonas, diamidinas aromáticas e aromáticas e as sobre Trypanosoma cruzi
EIA was the most active and selective against T. cruzi, encouraging the continuation of pre-clinical trials with representatives of this class in order to identification of new drugs for AD.
Inhibition of rhodesain as a novel therapeutic modality for human African trypanosomiasis.
The main classes of rhodesain inhibitors are discussed, including peptidic, peptidomimetic, and nonpeptidic structures, emphasizing those that have exhibited an optimal match between enzymatic affinity and trypanocidal profile and those for which preclinical investigations are currently in progress.
Instituto Oswaldo Cruz
The prevalence and parasitemia of Hepatozoon caimani in the natural population of the caiman, Caiman yacare, from the Pantanal area, state of Mato Grosso do Sul, central Brazil, were evaluated according to gender and month of capture and indicate that caimans are infected for the first time as juveniles.
Synthesis and evaluation of monoamidoxime derivatives: toward new antileishmanial compounds.
Synthesis and Antimalarial Activities of a Diverse Set of Triazole‐Containing Furamidine Analogues
One of these prodrugs, OB216, proved to be highly potent in vivo with an ED50 value of 5 mg kg−1 (po) and an observed 100 % cure rate (CD100) by oral administration in mice infected with P. vinckei.


Pneumocystis carinii pneumonia: a review of current issues in diagnosis and management
A review of 15 cases of bronchoscopically proven PCP admitted to the Royal Free Hospital between January 1998 and August 2000 revealed that seven patients were unaware of their HIV serostatus.
Why does Pneumocystis carinii pneumonia still occur?
Despite the effectiveness of these therapies, PCP remained the most common AIDS-de®ning opportunistic infection in the USA in 1997, the last year that national data were published on AIDS indicator diseases.
Pneumocystis pneumonia.
Advances that have resulted from studies of the cell biology, biochemistry, and genetics of pneumocystis in the past several years are summarized and recommendations for the diagnosis and treatment are included, as well as for prophylaxis and treatment.
Trimethoprim‐sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial
TMP-SMX and pentamidine are of equivalent efficacy as initial therapies for PCP in patients with AIDS.
Comparison of Three Regimens for Treatment of Mild to Moderate Pneumocystis carinii Pneumonia in Patients with AIDS: A Double-Blind, Randomized Trial of Oral Trimethoprim-Sulfamethoxazole, Dapsone-Trimethoprim, and Clindamycin-Primaquine
Although dapsone-trimethoprim and clindamycin-primaquine have gained widespread use in the treatment of P. carinii pneumonia, their relative efficacies have not yet been validated in a large controlled trial, and their toxicity profiles have not been directly compared.
Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure
Patient non-adherence was the most common reason for the occurrence of PCP among patients in HIV care; provider non- adherence was uncommon.
Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial.
In patients with AIDS, trimethoprim-sulfamethoxazole and pentamidine do not have statistically significant differences in efficacy or frequency of adverse reactions, and the two groups did not differ significantly in the severity of pulmonary or systemic processes at enrollment.
Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.
For the treatment of P. carinii pneumonia, atovaquone is less effective than trimethoprim-sulfamethoxazole, but it has fewer treatment-limiting adverse effects.
Adjunctive folinic acid with trimethoprim-sulfamethoxazole for Pneumocystis carinii pneumonia in AIDS patients is associated with an increased risk of therapeutic failure and death.
Folinic acid use was associated with a higher rate of both therapeutic failure and death and time to therapeutic failure was shorter and probability of death greater in patients receiving folinic acid, even when adjusted for baseline arterial oxygen pressure, serum lactate dehydrogenase, respiratory rate, CD4 cell count, and peak serum level of trimethoprim or sulfamethoxazole.
Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group.
  • E. Toma, Anona Thorne, R. Therrien
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1998
This trial confirms that Cm/Prq is a reasonable alternative therapy for mild and moderately severe PCP.